title: A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life.
abstract: We have previously reported that recombinant human granulocyte colony-stimulating factor was well tolerated and resulted in sustained neutrophilia and improvement of neutrophil functions in newborn infants with presumed sepsis. We now report a 2-year follow-up on 21 of the initial cohort of 28 patients. Treatment with recombinant human granulocyte colony-stimulating factor in neonates with presumed sepsis was not associated with any long-term adverse hematologic, immunologic, or developmental effects.
authors.affiliation: Division of Hematology/Oncology, Children's Hospital of Orange County, Orange, California 92668, USA.
authors.forename: J
authors.initials: J
authors.lastname: Rosenthal
authors.forename: T
authors.initials: T
authors.lastname: Healey
authors.forename: R
authors.initials: R
authors.lastname: Ellis
authors.forename: E
authors.initials: E
authors.lastname: Gillan
authors.forename: M S
authors.initials: MS
authors.lastname: Cairo
mesh_terms: D001772:Blood Cell Count; D002657:Child Development / Q000502:physiology; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D007136:Immunoglobulins; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor